CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

William Ho

Chief Executive Officer, In8bio

Search every verified William Ho interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. William Ho, co-founder and CEO of IN8bio, discussed the company’s work in developing gamma delta T cell therapies for blood cancers and solid tumors, including glioblastoma, in a June 2026 episode of the Business of Biotech podcast. He described the company’s strategy of addressing delivery and trafficking unknowns to reduce risk in clinical trials, citing early examples from other firms. Ho also recounted IN8bio’s experience navigating a difficult IPO market, including a 2021 pricing and a 2022 refiling, and spoke about managing layoffs and restructuring while preserving core programs. Ho offered his perspective on the current state of CAR-T and cell therapy, describing the field as still challenging and expressing skepticism about in vivo CAR-T as a universal solution, despite recent large preclinical deals. He also commented on the financial pressures of conducting research in the U.S., noting rising costs for non-human primate studies and questioning the long-term viability of U.S.-based timelines and pricing.

Recent appearances

  • Keeping An Early-Stage Cell Therapy Biotech In The Black With IN8bio's William Ho

    June 21, 2026 · 📺 Life Science Connect

    On this week's episode of the Business of Biotech, William Ho, CEO of IN8bio, explains why gamma delta T cells may have an edge against cancer, including solid tumors like glioblastoma. He also offers up a candid and step-by-step look at what it takes to finance an early clinical-stage cell therapy company through a punishing IPO market and a long cash crunch. Access this and hundreds of episodes of the Business of Biotech videocast at lifescienceleader.com --- #businessofbiotech #biopharma #biotech Subscribe to the podcast: Apple - https://podcasts.apple.com/us/podcast... Spotify - https:…

    Watch on YouTube ↗

  • In8bio (INAB) | Biotech Resurgence Conference Replay

    April 20, 2026 · 📺 RedChip Companies

    Glioblastoma remains one of the most difficult cancers to treat, which is why companies showing durable survival signals and differentiated immune-cell strategies are drawing increased investor attention. In this replay of IN8bio’s (Nasdaq: INAB) presentation and Q&A from RedChip’s Biotech Resurgence conference, CEO and co-founder William Ho explains how the company is advancing gamma-delta T-cell programs in oncology and autoimmune disease. Watch this presentation and Q&A to learn about: • Updated glioblastoma data showing repeat-dose patients achieved longer progression-free survival versus…

    Watch on YouTube ↗

  • The Chris Voss Show Podcast – Unlocking the Secrets of Cancer: IN8bio CEO William Ho, on Revoluti...

    August 25, 2025 · 📺 Chris Voss

    Unlocking the Secrets of Cancer: IN8bio CEO William Ho, on Revolutionizing Cancer Treatment In8bio.com About the Guest(s): William Ho is the director, president, CEO, and co-founder of IN8bio, a biotechnology company focusing on immune cell technologies to combat diseases like cancer. With a career spanning nearly 24 years in the biotechnology and healthcare investment sectors, William previously served as managing partner at Aleph Point Capital and held positions with New Leaf Venture Partners. His extensive experience in venture capital and biotechnology has shaped his leadership in pione…

    Watch on YouTube ↗

  • William Ho - CEO, IN8bio - Next Generation Cell Therapies For Cancer

    July 14, 2025 · 📺 Progress, Potential, and Possibilities

    William Ho is a Co-Founder, and has served as the President, Chief Executive Officer, and Director of IN8bio ( https://in8bio.com/ ), a biotech company with a mission of developing next-generation therapies for treating cancer, with a focus on gamma-delta T cells, since its inception. Mr. Ho has worked in the biotechnology industry for nearly 24 years. Prior to the founding of IN8bio, from 2014 to 2017, Mr. Ho was the Founder and Managing Partner at AlephPoint Capital, a private healthcare investment fund. Prior to that, Mr. Ho was at New Leaf Venture Partners, a leading healthcare ventur…

    Watch on YouTube ↗

  • IN8bio's CEO Unveils Gamma-Delta (γδ) T Cell Engager Platform for Cancer & Autoimmune Diseases

    March 03, 2025 · 📺 IN8bio

    IN8bio's CEO, William Ho, speaks at the TD Cowen 45th Annual Health Care Conference 2025 and unveils their next-generation gamma-delta T cell platform. INB-600 is a breakthrough next-generation γδ T cell-based TCE platform designed to address one of the biggest shortcomings of current existing γδ TCEs – insufficient numbers of γδ T cell effector cells to drive real clinical impact. This technology is designed to efficiently eliminate target cells while stimulating γδ T cell expansion to drive deeper and potentially longer-lasting immune responses. About IN8bio: IN8bio is a clinical-stage b…

    Watch on YouTube ↗

  • What was the inspiration behind starting IN8bio?

    August 30, 2024 · 📺 IN8bio

    Our CEO and co-founder, William Ho, looks back at his past and the inspiration behind founding IN8bio. From a career in finance to pioneering cancer treatments, discover how a chance encounter and a blizzard in 2015 led to the birth of IN8bio. Please join us on our journey to transform cancer therapy with gamma-delta T cells! #CancerZero #GammaDeltaTCells #Biotech #CancerResearch #Entrepreneurship

    Watch on YouTube ↗

  • What was our inspiration for pursuing gamma-delta T cells? Hear from IN8bio’s CEO, William Ho

    August 06, 2024 · 📺 IN8bio

    Join our CEO, William Ho, as he shares the heartfelt inspiration behind IN8bio's focus on gamma-delta T cells. Our Chief Scientific Officer, Dr. Lawrence Lamb, PhD, was deeply moved by his experience with six young #leukemia patients in the 1990s, leading him to a lifelong mission. Discover how gamma-delta T cells, with the unique ability to distinguish between healthy and cancerous tissue, are at the core of our groundbreaking cancer therapies. Please watch for more about the story and learn about our innovative DeltEx platform. Together, we're pushing the boundaries of science to achieve #C…

    Watch on YouTube ↗

  • Why gamma-delta T cells?

    October 10, 2023 · 📺 IN8bio

    Why gamma-delta T cells? We believe they sit in a unique sweet spot, between alpha-beta T cells, which are remarkably powerful but also toxic, and natural killer (NK) cells, which kill directly but lack persistence. #gdTcells combine the best of both. $INAB #IN8bio #CancerZero

    Watch on YouTube ↗

  • IN8bio's CEO, William Ho | Fireside Chat at H.C. Wainwright's Annual Global Investment Conference.

    September 21, 2023 · 📺 IN8bio

    People have said solid tumors like glioblastoma are too difficult to study. We disagree. Here’s how we are approaching the battle. Our CEO, William Ho, sat down last week for a fireside chat with Swayampakula Ramakanth at H.C. Wainwright's 25th Annual Global Investment Conference.

    Watch on YouTube ↗

  • William Ho, CEO of IN8Bio on NewYorkBIO's #VirtualBreakfastSeries

    September 13, 2021 · 📺 NewYorkBIO Video Channel

    NewYorkBIO's breakfast series has gone virtual! Providing engaging speakers on innovation, clinical development, patient engagement and more cutting topics across the biopharmaceutical industry. These events are held live every Tuesday morning at 9AM with open registration for all interested participants. Learn more about our organization at www.newyorkbio.org and follow us on Twitter @NewYorkBIO

    Watch on YouTube ↗

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →